Disc Medicine (IRON) said late Wednesday it priced its public offering of common stock and pre-funded warrants for gross proceeds of about $225.5 million, upsized from the initial offering of $200 million.
The company said it is selling about 3.9 million shares and pre-funded warrants to purchase 181,818 shares. The common shares are being sold at $55 per share, while the warrants are being sold at $54.9999 per warrant.
Underwriters have been granted a 30-day option to purchase up to about $33.8 million additional shares.
Proceeds from the offering, set to close on Friday, would be used to fund research and clinical development of its product candidates, support the potential commercialization of bitopertin for erythropoietic protoporphyria and X-linked protoporphyria, and for general corporate purposes, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。